ReviewCurrent hematologic malignancy reports2010
Targeting chronic myeloid leukemia stem cells.
Review in Current hematologic malignancy reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics.Frontiers in pharmacology · 2025Review
- Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.Journal of cellular and molecular medicine · 2020Article
- The Posterior Signaling Center Is an Important Microenvironment for Homeostasis of theFrontiers in cell and developmental biology · 2020Review
- Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.Wiener klinische Wochenschrift · 2018Review
- Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models.Stem cells international · 2016Review
- Article
- New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Stem cells, redox signaling, and stem cell aging.Antioxidants & redox signaling · 2014Review
- Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.Antioxidants & redox signaling · 2014Article
- Stem cell maintenance and disease progression in chronic myeloid leukemia.International journal of hematology · 2013Review
- The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia.The Journal of pathology · 2013Article
- What challenges remain in chronic myeloid leukemia research?Haematologica · 2013Article
- Article
- The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Leukemia research and treatment · 2012Article
- Cancer, stem cells and cancer stem cells: old ideas, new developments.F1000 medicine reports · 2011Article
- From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.Genes & cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known molecular basis of CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate. However, the success of tyrosine kinase inhibitors, as rationally designed first-line therapies, has been tempered by problems of disease persistence and resistance. Residual disease has been shown to be enriched within the stem cell compartment and to persist at stable levels for up to 5 years of complete cytogenetic response. This finding has led to further searches for novel strategies aimed at eliminating these cells; such strategies may be essential in achieving cure. The most significant recent findings are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.